<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545516</url>
  </required_header>
  <id_info>
    <org_study_id>Post Cesarean Pain Management</org_study_id>
    <nct_id>NCT03545516</nct_id>
  </id_info>
  <brief_title>Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery</brief_title>
  <official_title>Randomized Control Trial for an Opioid Free Analgesic Pathway Post Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richmond University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Richmond University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of three types of wound infiltration on post Cesarean
      opioid analgesia consumption when used in conjunction with an opioid free postoperative
      analgesia pathway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects that meet the inclusion criteria of the study will be randomized preoperatively
      into three arms following a 1:1:1 ratio. During the intraoperative course one of three
      combinations of wound infiltration will be administered to subjects prior to the closure of
      the surgical incision. Subjects in Group I will receive a placebo of normal saline. Subjects
      in Group II will receive bupivacaine alone. Subjects in Group III will receive both
      bupivacaine and dexmedetomidine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 17, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of opioid free Cesarean deliveries</measure>
    <time_frame>1 year</time_frame>
    <description>Measure the number of Cesarean deliveries that did not require opioid analgesia during the postoperative course</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue analgesia</measure>
    <time_frame>0 hour post-cesarean to time rescue analgeisa is administered]</time_frame>
    <description>Measure the time to first rescue analgesia from immediate post operative (0 hour) till when the rescue analgesia is administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>0-14 days</time_frame>
    <description>Measure the subjects total opioid consumption for the total duration of the postoperative course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects/Adverse reactions</measure>
    <time_frame>0-14 days</time_frame>
    <description>Measure any side effects/allergic reactions attributed to use of any of the study drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>0-14days</time_frame>
    <description>Measure the length of the post-operative hospital stay .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications from procedures</measure>
    <time_frame>0-14 days</time_frame>
    <description>Measure any complications associated with the wound infiltration procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast feeding capacity</measure>
    <time_frame>0-14 days</time_frame>
    <description>Assess the subject's capacity to breast feed during the postoperative course</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Anesthesia, Local</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Wound infiltration with a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine and Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Injection of bupivacaine into the surgical incision prior to its closure.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine and Dexmedetomidine</arm_group_label>
    <other_name>Bupivacaine wound infiltration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.</description>
    <arm_group_label>Bupivacaine and Dexmedetomidine</arm_group_label>
    <other_name>Dexmedetomidine wound infiltration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of a placebo into the surgical wound</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All scheduled Cesarean deliveries with intrathecal or epidural anesthesia

        Exclusion Criteria:

          -  Emergency Cesarean deliveries

          -  Multifetal gestation

          -  Subjects &lt;18 years old

          -  Subjects belonging to a vulnerable population (including subjects with a known opioid
             addiction, subjects with a history of mental illness and prisoners)

          -  Cesarean delivery with general anesthesia

          -  Known allergy or hypersensitivity to any of the study medications

          -  Subjects that can't comprehend the visual analog scale for quantitative pain
             assessment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Lakhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisha Lakhi, MD</last_name>
    <phone>718-818-2109</phone>
    <email>NLAKHI@RUMCSI.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Richmond University Medical Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Richmond University Medical Center</investigator_affiliation>
    <investigator_full_name>Nisha Lakhi, MD</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <keyword>Wound infiltration</keyword>
  <keyword>Post Cesarean</keyword>
  <keyword>Pain management</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

